

WHAT IS THAT?

Kevin Sexton





National Comprehensive Cancer Network

Your Best Resource in the Fight Against Cancer®

 [NCCN Guidelines™ & Clinical Resources](#)[Educational Events & Programs](#)[NCCN Research & Business Resources](#)[About NCCN](#)[Subscriptions & Products](#)[For Patients](#)

NCCN Guidelines™

[NCCN Guidelines User System \(GUS™\)](#)[Recent Updates to NCCN Guidelines™](#)[NCCN Categories of Evidence and Consensus](#)[NCCN Guidelines™ Steering Committee](#)[Submission Request to the NCCN Guidelines Panels](#)[Submission Request History](#)[NCCN Guidelines Panels - Meeting Schedule](#)[Permissions Requests](#)[End User License Agreement](#)[NCCN Compendium™](#)[NCCN Templates™](#)[NCCN Mobile Applications](#)[International Adaptations and Translations](#)[NCCN 在中国-全新中文网站](#)[NCCN Flash Updates™](#)[On-line Catalog](#)[JNCCN - The Journal of the National Comprehensive Cancer Network](#)[NCCN Disclosure Policies & Potential Conflicts of Interest](#)[Upcoming Events](#)[CME/CE Programs](#)

Legend

NCCN Guidelines™

NCCN Guidelines™ & Clinical Resources

NCCN Guidelines™

Registration and Access to the NCCN Guidelines™ is FREE. You must [Login](#) or [Register](#) to access this information.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) are posted with the latest update date and version number.

NCCN Mobile Applications - Access the NCCN Guidelines anywhere and at anytime through free NCCN Guidelines mobile apps for iPhone and Android.

The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. [Permissions Requests Section](#)

[View the NCCN Guidelines Panel Members individual disclosures](#)

NCCN Guidelines for Treatment of Cancer by Site

NCCN Guidelines for Detection, Prevention, & Risk Reduction

NCCN Guidelines for Supportive Care

NCCN Guidelines for Treatment of Cancer by Site

You must [Login](#) or [Register](#) to access this information.

[Acute Myeloid Leukemia](#)[Anal Carcinoma](#)[Bladder Cancer](#)

- Bladder Cancer
- Upper Tract Tumors
- Urothelial Carcinoma of the Prostate

[E-mail](#) [Print](#) [Mark](#) [A](#) [A](#) [Size](#)[Log in](#)

Quick Links

[NCCN Guidelines™ - FREE](#)[NCCN Compendium™](#)[NCCN Templates™](#)[Educational Events](#)[CME/CE Programs](#)

Upcoming Events

Surgical Management of Head and Neck Cancer - (8/9/2011)

NCCN Guidelines Update Webinar Series™: Melanoma - (8/10/2011)

Systemic Therapy for Head and Neck Cancer - (8/10/2011)

[more](#)

[Register Now!](#)[CME/CE Available](#)

NCCN Guidelines Update Webinar Series™

Melanoma

What makes you suspicious a skin lesion is melanoma?

- Asymmetry
- Borders (irregular)
- Color
- Diameter >6 mm
- Evolving over time

Nodular Melanoma

- Elevated above the skin surface
- Firm to the touch
- Growing.



How do you diagnose melanoma?

- Shave Biopsy
- Excisional Biopsy
- Punch Biopsy



ML

- 56yo male underwent WLE and SLNBx in 09/09 for R scalp melanoma
- Path:
 - superficial spreading melanoma
 - Clark's Level III/IV
 - Breslow Thickness 1.1 mm
 - SLN Bx: Benign Nevus Cells in Parotid Tissue




Types of Melanoma

- Superficial Spreading
 - Most common (70%), spreads along epidermis
- Nodular
 - 15-30%, Grows Deeper faster
- Lentigo Maligna
 - 5%, arises from sunspot
- Acral Lentiginous
 - <5% but most common in AA or Asians
 - Palms, soles, nails



Breslow and Clark



Margins Needed

Tumor Thickness	Resection Margin
In Situ	0.5 cm
≤ 1.0 mm	1.0 cm
1.1 – 2 mm	1-2 cm
2.01 – 4 mm	2 cm
> 4 mm	2 cm

These are based on clinical margins taken at the time of surgery, not gross or histologic margins as determined by the pathologist.



Benign Pigmented Cells in Parotid

- Can you find melanocytes in the parotid?
- Superficial parotidectomy & neck dissection
 - Parotid: Melanoma in transit + 3 periglandular LN +
 - Neck nodes (23) all negative
- Adjuvant chemo (temozolamide) + XRT

But then things got worse...





Remington.

- Presents to med-onc at VUMC 2/2010 for discussions of trials as tumor recurred & deemed unresectable
 - Staged IVa: median survival of 12 months
 - Alphabet soup chemo trial
 - Tumor not responsive based on *in vitro* genetic testing
 - High dose IL-2 recommended
 - Instituted 4/2010→ stopped for arrhythmia requiring pressors
- Rad Onc→ we can't do anything
- Surgical Palliation
 - PET (-) except for head and neck, brain MR (-)





5321

11/08/2010

19:11:32

19:15:58

Comment: CORONAL NECK

Referring: PUZANOV, IGOR, MD,

Requesting:

056Y

M

R

1

4

9

kV:120

mas435

2mm

DFOV284

TILT:0

ALG:B

140mm

CT1012

L
1
6
5

Operator: SEJ/EQ

IM:71

SE:80317

CTN2

CONTRAST: CONTRAST

58





5321

11/08/2010

19:11:32

19:15:58

Comment: CORONAL NECK

Referring: PUZANOV, IGOR, MD,

Requesting:

056Y

M

R

1

4

9

kV:120

mas435

2mm

DFOV284

TILT:0

ALG:B

140mm

CT1012

L

1

6

5

Operator: SEJ/EQ

IM:71

SE:80317


CTN2


CONTRAST: CONTRAST

58










Whether you take the ladder or the elevator, it gets more complex at the top.

The Reconstructive Triangle


Flaps / Grafts





Tissue Expansion


Microsurgery




























Remingt